177Lu-PSMA Radioligand Therapy for Prostate Cancer
- PMID: 28663195
- DOI: 10.2967/jnumed.117.191023
177Lu-PSMA Radioligand Therapy for Prostate Cancer
Erratum in
-
Errata.J Nucl Med. 2018 Feb;59(2):346. J Nucl Med. 2018. PMID: 29419456 No abstract available.
Abstract
177Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. The current literature suggests that this therapy is well tolerated and effective. On the basis of clinical need and current evidence, the therapy is being implemented in a growing number of centers worldwide. Here, we review important aspects of 177Lu-PSMA RLT, including patient stratification, the therapy protocol, concomitant medication, and follow-up, to inform medical staff involved in the RLT and care of patients with metastatic castration-resistant prostate cancer.
Keywords: PSMA; education; genitourinary; lutetium; radionuclide therapy; therapy.
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.
Similar articles
-
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.J Med Radiat Sci. 2017 Mar;64(1):52-60. doi: 10.1002/jmrs.227. J Med Radiat Sci. 2017. PMID: 28303694 Free PMC article. Review.
-
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):496-508. doi: 10.1007/s00259-017-3895-x. Epub 2017 Dec 16. Eur J Nucl Med Mol Imaging. 2018. PMID: 29247284 Free PMC article.
-
[PSMA-targeted radioligand therapy in prostate cancer].Urologe A. 2017 Jan;56(1):32-39. doi: 10.1007/s00120-016-0274-3. Urologe A. 2017. PMID: 27885457 Review. German.
-
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22. Eur J Nucl Med Mol Imaging. 2019. PMID: 31440799
-
Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.Theranostics. 2024 Apr 8;14(6):2560-2572. doi: 10.7150/thno.93249. eCollection 2024. Theranostics. 2024. PMID: 38646643 Free PMC article.
Cited by
-
177 Lutetium SPECT/CT: Evaluation of collimator, photopeak and scatter correction.J Appl Clin Med Phys. 2020 Sep;21(9):272-277. doi: 10.1002/acm2.12991. Epub 2020 Aug 13. J Appl Clin Med Phys. 2020. PMID: 32790140 Free PMC article.
-
Simulation studies of a full-ring, CZT SPECT system for whole-body imaging of 99m Tc and 177 Lu.Med Phys. 2023 Jun;50(6):3726-3737. doi: 10.1002/mp.16360. Epub 2023 Mar 22. Med Phys. 2023. PMID: 36916755 Free PMC article.
-
Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.Mol Pharm. 2019 Sep 3;16(9):3831-3841. doi: 10.1021/acs.molpharmaceut.9b00464. Epub 2019 Aug 16. Mol Pharm. 2019. PMID: 31381351 Free PMC article.
-
Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives.Cancers (Basel). 2023 Sep 27;15(19):4746. doi: 10.3390/cancers15194746. Cancers (Basel). 2023. PMID: 37835440 Free PMC article. Review.
-
Distribution of prostate specific membrane antigen (PSMA) on PET-MRI in patients with and without ovarian cancer.Abdom Radiol (NY). 2023 Dec;48(12):3643-3652. doi: 10.1007/s00261-023-03957-3. Epub 2023 Jun 1. Abdom Radiol (NY). 2023. PMID: 37261441
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
